There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD) and a history of cancer, ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who ...
A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.
Organ transplantation is fraught with challenges, from donor shortages to eventual transplanted organ failure. The immunosuppressive drugs that are currently the standard of care following ...
Eledon Pharmaceuticals announced that their investigational anti-CD40L antibody, tegoprubart, was successfully used in the immunosuppression regimen for a patient who recently received a kidney ...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results